Lockheed Martin CEO says company pouring billions into missile output after Trump’s defense push

Lockheed Martin is accelerating weapons production and capex, investing $3.6 billion in capex and IRAD in 2025 and planning to increase that to $5.0 billion in 2026 (a 35% rise) in response to policy pressure to prioritize manufacturing over buybacks. The company will quadruple THAAD output from roughly 96 to 400 units annually over the next three years, broke ground on a munitions acceleration center in Arkansas, and signed a seven-year agreement to boost PAC-3 MSE production to about 2,000 interceptors per year; shares rose ~6% after earnings and updated guidance. These moves materially increase Lockheed’s production capacity and signal a strategic shift toward internal investment and defense build-up that is likely to influence defense sector allocations.

Analysis

Market structure: Lockheed (LMT) is a clear near-term winner — 2026 capex rising from $3.6B to $5B (+35%) and a THAAD build-rate jump from ~96 to 400 units over three years materially shifts airborne/ABM supply concentration to primes. Suppliers of precision electronics, specialty alloys and missile seekers (beneficiaries include RTX, NOC, GD supply chains) should see multi-year revenue visibility; consumer-facing defense contractors that rely on buybacks may be disadvantaged politically and competitively. Increased DoD long-duration contracts (seven-year PAC‑3 MSE ramp to ~2,000/yr) implies less spot-price competition and stronger pricing power for capacity holders.

Risk assessment: Tail risks include a reversal of procurement policy under political change, congressional appropriations shortfalls, or severe production bottlenecks (semiconductor/skill shortages) that blow 20–40% of expected delivery rates. Immediate (days) risk: post-earnings multiple expansion may retrace; short-term (weeks–months) risk: supplier bottleneck headlines; long-term (years) risk: capex failing to convert to free cash flow if margins erode or contracts are cost-plus. Hidden dependency: production ramp relies on tier‑2/3 subcontractors and export controls; catalysts to watch are DoD award notices, weekly backlog updates and congressional defense spending votes.

Trade implications: Tactical: establish a 2–3% long position in LMT over 1–12 months to capture production rerating, scaling in over 3 tranches as monthly backlog confirms ramp; complement with 1–2% longs in RTX and NOC as supply-chain plays. Relative-value: long LMT vs short small-cap defense names lacking secured multi-year contracts or high buyback exposure (XAR underperformers) to exploit funding/scale advantage. Options: buy 6–12 month call spreads on LMT to limit premium outlay or sell near-term covered calls to monetize a high-probability pop (target +15–25% upside exit).

Key Decisions for Investors

• Establish a 2–3% long position in LMT within 1–5 trading days, scale in three equal tranches over 3 months; target horizon 6–12 months and take profits if position rises +25% or if 2 consecutive months of backlog cadence misses guidance.
• Add 1% positions in RTX and NOC as supply-chain exposure (hold 6–18 months); trim if supplier lead-time reports show >20% slip or semiconductor shortages surface.
• Implement a 6–12 month LMT call spread to express upside with defined risk (buy ITM/near-ATM call, sell higher strike ~20–30% out) sized to cap portfolio risk at ~0.5–1% of NAV.
• Pair trade: go long LMT (2%) and short 1–1.5% in a small-cap defense ETF or name with >50% cash returns and no multi-year contracts (rotate if XAR underperforms by >5% relative to LMT over 30 days).
• Monitor triggers for liquidation: any failure to secure required FY appropriations or two consecutive monthly backlog misses → reduce LMT exposure by 50% within 7 trading days.